QUTE-CE MRI
Diagnostic Imaging (Quantitative Angiography)
Phase 1Active
Key Facts
About Theranano
Theranano is a private, pre-revenue biotech company founded in 2015, advancing a pipeline of nanomedicine-based therapeutic and diagnostic platforms. Its lead programs include the InCeRT implant for localized cancer therapy, which is in IND-enabling studies, and the QUTE-CE MRI contrast agent, which is in a first-in-human clinical trial. The company leverages the scientific expertise of its founder, Dr. Srinivas Sridhar, and a team of domain experts in research, regulatory affairs, and manufacturing, with strategic access to Boston's medical research ecosystem.
View full company profile